International Stem Cell (ISCO) Change in Accured Expenses (2010 - 2025)
International Stem Cell (ISCO) posted quarterly Change in Accured Expenses of -$24000.0 for Q4 2025, down 146.15% year-over-year from $52000.0 in Q4 2024, and up 87.94% quarter-over-quarter from -$199000.0 in Q3 2025.
International Stem Cell (ISCO) Change in Accured Expenses (2010 - 2025) Analysis & Trends
International Stem Cell (ISCO) has reported Change in Accured Expenses for 16 consecutive years, with -$24000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses fell 146.15% year-over-year to -$24000.0; the TTM figure through Dec 2025 stood at -$99000.0 (down 335.71% YoY), while the FY2025 annual figure was -$99000.0, down 335.71% from the prior year.
- Change in Accured Expenses climbed to -$24000.0 in Q4 2025 per ISCO's latest filing, from -$199000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $174000.0 in Q1 2021 and bottomed at -$237000.0 in Q3 2021.
- Historically, Change in Accured Expenses has averaged $2050.0 across 5 years, with a median of $15500.0 in 2022.
- Annual changes were most pronounced in 2021 — Change in Accured Expenses jumped 656.25% — and 2023, when it slumped 5450.0%.
- International Stem Cell's Change in Accured Expenses stood at $121000.0 in 2021, then slumped by 72.73% to $33000.0 in 2022, then soared by 30.3% to $43000.0 in 2023, then climbed by 20.93% to $52000.0 in 2024, then plunged by 146.15% to -$24000.0 in 2025.
- Business Quant data shows ISCO's Change in Accured Expenses at -$24000.0 in Q4 2025, -$199000.0 in Q3 2025, and $43000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24,000.00 |
| Dec 31, 2025 | -24,000.00 |
| Sep 30, 2025 | -199,000.00 |
| Sep 30, 2025 | -199,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Sep 30, 2024 | -95,000.00 |
| Sep 30, 2024 | -95,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | 93,000.00 |
| Mar 31, 2024 | 93,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Sep 30, 2023 | -79,000.00 |
| Sep 30, 2023 | -79,000.00 |